CL2008002549A1 - Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv. - Google Patents

Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv.

Info

Publication number
CL2008002549A1
CL2008002549A1 CL2008002549A CL2008002549A CL2008002549A1 CL 2008002549 A1 CL2008002549 A1 CL 2008002549A1 CL 2008002549 A CL2008002549 A CL 2008002549A CL 2008002549 A CL2008002549 A CL 2008002549A CL 2008002549 A1 CL2008002549 A1 CL 2008002549A1
Authority
CL
Chile
Prior art keywords
cocrystal
dihydroxybenzoic acid
acid
preparation
pharmaceutical composition
Prior art date
Application number
CL2008002549A
Other languages
English (en)
Inventor
Technologies Inc Retractable
J Shaw Thomas
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CL2008002549A1 publication Critical patent/CL2008002549A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cocristal de (1s,3ar,6as)-2-[(2s)-[[(2s)-2-ciclohexil-2-(pirazina-2-carbonilamino)acetil]amino]-3,3-dimetilbutanoil]-n-[(3s)-1-(ciclopropilamino)-1,2-dioxohexan-3-il]-3,3a,4,5,6,6a-hexahidro-1h-ciclopenta[c]pirrol-1-carboxamida y un solvente formador de cocristales como ácido 2,5-dihidrobenzoico; composición farmacéutica; métodos de preparación y modulación.
CL2008002549A 2007-08-30 2008-08-29 Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv. CL2008002549A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96902307P 2007-08-30 2007-08-30

Publications (1)

Publication Number Publication Date
CL2008002549A1 true CL2008002549A1 (es) 2010-09-03

Family

ID=40011185

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002549A CL2008002549A1 (es) 2007-08-30 2008-08-29 Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv.

Country Status (13)

Country Link
US (1) US8492546B2 (es)
EP (2) EP2185546B1 (es)
JP (1) JP5443360B2 (es)
CN (1) CN101835774B (es)
AR (1) AR068817A1 (es)
AT (1) ATE530546T1 (es)
AU (1) AU2008297015B2 (es)
CA (1) CA2704284A1 (es)
CL (1) CL2008002549A1 (es)
MX (1) MX2010002407A (es)
NZ (1) NZ583699A (es)
TW (1) TW200922933A (es)
WO (1) WO2009032198A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
EP2323622A1 (en) * 2008-09-03 2011-05-25 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
US9173391B2 (en) * 2009-11-06 2015-11-03 Basf Se Crystalline complexes of 4-hydroxy benzoic acid and selected pesticides
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
CN104383541A (zh) 2011-10-21 2015-03-04 艾伯维公司 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2935245A1 (en) * 2012-12-21 2015-10-28 Sandoz AG Novel forms of telaprevir
CN103497234B (zh) * 2013-09-24 2015-07-08 苏州永健生物医药有限公司 一种特拉匹韦中间体a晶型及其合成方法
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11952334B2 (en) 2018-08-03 2024-04-09 Center For Intelligent Research In Crystal Engineering, S.L. Cocrystals of ubiquinone and compositions comprising them

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5496927A (en) 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
EP0204571B1 (en) 1985-06-07 1992-01-22 Ici Americas Inc. Selected difluoro derivatives
US5231084A (en) * 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
US5736520A (en) * 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
NZ235155A (en) 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
US5371072A (en) 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
EP0604182B1 (en) * 1992-12-22 2000-10-11 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of Aids
DE69334250D1 (de) 1992-12-29 2009-01-29 Abbott Lab Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
US5656600A (en) * 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5672582A (en) * 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
AU1615895A (en) 1994-03-31 1995-10-12 Bristol-Myers Squibb Company Imidazole-containing inhibitors of farnesyl protein transferase
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
JP2000500760A (ja) * 1995-11-23 2000-01-25 メルク シヤープ エンド ドーム リミテツド スピロピペリジン誘導体およびタキキニン拮抗薬としてのその使用
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
SK286662B6 (sk) * 1996-04-23 2009-03-05 Vertex Pharmaceuticals Incorporated Deriváty močoviny, farmaceutické prostriedky, ktoré ich obsahujú, a ich použitie ako inhibítorov aktivity IMPDH enzýmu
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
EP0929554B1 (en) * 1996-09-25 2006-03-15 MERCK SHARP & DOHME LTD. Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists
JP2001502316A (ja) * 1996-10-08 2001-02-20 コロラド ステート ユニバーシティ リサーチ ファンデーション 触媒不斉エポキシ化
CA2268391A1 (en) 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE19648011A1 (de) * 1996-11-20 1998-05-28 Bayer Ag Cyclische Imine
WO1998040381A1 (en) * 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
GB9708484D0 (en) * 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
GB9711114D0 (en) * 1997-05-29 1997-07-23 Merck Sharp & Dohme Therapeutic agents
ES2234144T3 (es) 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. Analogos de peptidos inhibidores de la hepatitis c.
US6767991B1 (en) * 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6183121B1 (en) * 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
US20040058982A1 (en) * 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
WO1999028482A2 (en) * 1997-11-28 1999-06-10 Schering Corporation Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
JP4690545B2 (ja) * 1998-03-31 2011-06-01 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
US6251583B1 (en) * 1998-04-27 2001-06-26 Schering Corporation Peptide substrates for HCV NS3 protease assays
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (de) * 1998-08-12 2000-02-17 Univ Stuttgart Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
US6117639A (en) * 1998-08-31 2000-09-12 Vertex Pharmaceuticals Incorporated Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
US6025516A (en) * 1998-10-14 2000-02-15 Chiragene, Inc. Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
DE60039377D1 (de) * 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
US20020042046A1 (en) * 1999-02-25 2002-04-11 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
EP1964561A1 (en) * 1999-03-19 2008-09-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
US20020183249A1 (en) 1999-08-31 2002-12-05 Taylor Neil R. Method of identifying inhibitors of CDC25
EP1252178A1 (en) * 1999-12-03 2002-10-30 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
CA2396504A1 (en) * 2000-02-29 2001-09-07 Dupont Pharmaceuticals Company Inhibitors of hepatitis c virus ns3 protease
JP4806154B2 (ja) 2000-04-03 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
CA2405521C (en) * 2000-04-05 2010-06-29 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
CN1432022A (zh) * 2000-04-19 2003-07-23 先灵公司 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂
US7419678B2 (en) 2000-05-12 2008-09-02 Cordis Corporation Coated medical devices for the prevention and treatment of vascular disease
EP2289888A3 (en) * 2000-06-30 2011-07-13 Seikagaku Corporation Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
JP2004504407A (ja) * 2000-07-21 2004-02-12 コルバス・インターナショナル・インコーポレイテッド Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
IL153670A0 (en) 2000-07-21 2003-07-06 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
CN1446201A (zh) 2000-07-21 2003-10-01 先灵公司 用作丙型肝炎病毒ns3－丝氨酸蛋白酶抑制剂的新型肽
AR034127A1 (es) * 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
AU2002248147B2 (en) 2000-11-20 2006-04-06 Bristol-Myers Squibb Company Hepatitis C tripeptide inhibitors
KR20030091946A (ko) 2000-12-12 2003-12-03 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 디아릴 펩티드
US6653295B2 (en) * 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
US6727366B2 (en) * 2000-12-13 2004-04-27 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
EP1355916B1 (en) 2001-01-22 2007-01-10 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US20020187488A1 (en) 2001-01-30 2002-12-12 Chao Lin Quantitative assay for nucleic acids
WO2002077206A1 (en) 2001-03-27 2002-10-03 Vertex Pharmaceuticals Incorporated Compositiona and methods useful for hcv infection
GB0107924D0 (en) * 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
NZ530000A (en) * 2001-07-11 2007-03-30 Vertex Pharma Peptidomimetic bridged bicyclic serine protease inhibitors
JP2003055389A (ja) 2001-08-09 2003-02-26 Univ Tokyo 錯体及びそれを用いたエポキシドの製法
DE10140234A1 (de) * 2001-08-22 2003-03-13 Karmann Gmbh W Cabriolet-Fahrzeug mit einem zumindest bereichsweise flexiblen Dach
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
US20030229390A1 (en) 2001-09-17 2003-12-11 Control Delivery Systems, Inc. On-stent delivery of pyrimidines and purine analogs
MXPA04003825A (es) 2001-10-24 2004-07-08 Vertex Pharma Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado.
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
CN1612866A (zh) * 2001-11-14 2005-05-04 特瓦制药工业有限公司 无定形和结晶形的氯沙坦钾及其制备方法
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1497282A2 (en) * 2002-04-11 2005-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4 protease
US20030204168A1 (en) 2002-04-30 2003-10-30 Gjalt Bosma Coated vascular devices
US6835387B2 (en) 2002-06-11 2004-12-28 Scimed Life Systems, Inc. Sustained release of superoxide dismutase mimics from implantable or insertable medical devices
MXPA05001298A (es) * 2002-08-01 2005-11-04 Pharmasset Inc Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae.
JP4027751B2 (ja) 2002-08-23 2007-12-26 横浜ゴム株式会社 タイヤ用ホイールセット及びそれを装着した車両
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US6715452B1 (en) 2002-11-13 2004-04-06 Arvin Technologies, Inc. Method and apparatus for shutting down a fuel reformer
CA2413705A1 (en) * 2002-12-06 2004-06-06 Raul Altman Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
EP1596846A2 (en) 2003-02-18 2005-11-23 Pfizer Inc. Inhibitors of hepatitis c virus, compositions and treatments using the same
WO2004101605A1 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
JP4682140B2 (ja) 2003-03-05 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類縁体
CN100453553C (zh) 2003-04-11 2009-01-21 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
TW200510391A (en) 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2004240704B9 (en) * 2003-05-21 2009-10-22 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor compounds
KR20120013450A (ko) 2003-07-18 2012-02-14 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의 억제제
BRPI0413076B8 (pt) * 2003-07-29 2021-07-27 Abbot Laboratories Gmbh processo analítico para composições de pancreatina e comparáveis
MY148123A (en) * 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
RU2006115558A (ru) 2003-10-10 2007-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы
RU2006118359A (ru) * 2003-10-27 2007-12-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Комбинации для лечения вирусного гепатита с (hcv)
WO2005043118A2 (en) * 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
US7494660B2 (en) 2003-10-27 2009-02-24 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease resistance mutants
DE602004023105D1 (de) 2003-10-28 2009-10-22 Vertex Pharma HERSTELLUNG VON 4,5-DIALKYL-3-ACYLPYRROL-2-CARBONS ANSCHLIEßENDE ACYLIERUNG
US7132504B2 (en) * 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2007516706A (ja) 2003-12-01 2007-06-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド 胎児肝臓細胞を含む組成物およびｈｃｖ感染で有用な方法
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
CN1938332B (zh) 2004-02-04 2011-10-19 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
DK1718608T3 (da) 2004-02-20 2013-10-14 Boehringer Ingelheim Int Virale polymeraseinhibitorer
JP2007525512A (ja) 2004-02-27 2007-09-06 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしての３，４−（シクロペンチル）−縮合プロリン化合物
SG150546A1 (en) 2004-03-12 2009-03-30 Vertex Pharma Processes and intermediates
AR049635A1 (es) 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
KR101370580B1 (ko) * 2004-06-08 2014-03-06 버텍스 파마슈티칼스 인코포레이티드 약학 조성물
EP1604697A1 (en) 2004-06-09 2005-12-14 J.A.C.C. GmbH Implantable device
US8999364B2 (en) 2004-06-15 2015-04-07 Nanyang Technological University Implantable article, method of forming same and method for reducing thrombogenicity
JP5017103B2 (ja) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
JP2008511633A (ja) * 2004-08-27 2008-04-17 シェーリング コーポレイション Ｃ型肝炎ウィルスｎｓ３セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物
RU2007116265A (ru) 2004-10-01 2008-11-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибирование протеазы ns3-ns4a вируса hcv
TW201424733A (zh) * 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
WO2006124823A2 (en) 2005-05-13 2006-11-23 Alveolus Inc. Intravascular implant delivery device with anchoring features and associated method
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
MX2008001528A (es) * 2005-08-02 2008-04-04 Vertex Pharma Inhibidores de serina proteasas.
KR20140069370A (ko) * 2005-08-19 2014-06-09 버텍스 파마슈티칼스 인코포레이티드 방법 및 중간체
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007030478A2 (en) 2005-09-06 2007-03-15 Light Sciences Oncology, Inc. Implantable device for therapeutic treatment within a body lumen
CA2621666A1 (en) * 2005-09-09 2007-03-15 Universitaet Zuerich Antigens for vaccination against and detection of mycoplasma suis
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP1991229A2 (en) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
BRPI0709567A2 (pt) 2006-03-16 2011-07-12 Vertex Pharma inibidores deuterados de protease de hepatite c
CA2646123A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Processes and intermediates for preparing steric compounds
KR20140107691A (ko) 2006-03-20 2014-09-04 버텍스 파마슈티칼스 인코포레이티드 의약 조성물
US20070218138A1 (en) 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
US20100003634A1 (en) 2006-04-25 2010-01-07 D B Orthodontics Ltd Orthodontic implant device
ATE481089T1 (de) 2006-05-31 2010-10-15 Vertex Pharma Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting- enzyme inhibitors
EP2077797A4 (en) 2006-08-28 2010-07-21 Cornova Inc IMPLANTABLE DEVICES AND METHODS OF FORMATION THEREOF
BRPI0807261B8 (pt) 2007-02-09 2021-06-22 Taheri Laduca Llc conjuntos de cateter carregado com stent

Also Published As

Publication number Publication date
ATE530546T1 (de) 2011-11-15
US20110009424A1 (en) 2011-01-13
CN101835774A (zh) 2010-09-15
AU2008297015A1 (en) 2009-03-12
MX2010002407A (es) 2010-03-26
CA2704284A1 (en) 2009-03-12
AU2008297015B2 (en) 2013-08-22
TW200922933A (en) 2009-06-01
EP2436682A1 (en) 2012-04-04
NZ583699A (en) 2012-04-27
US8492546B2 (en) 2013-07-23
JP5443360B2 (ja) 2014-03-19
AR068817A1 (es) 2009-12-09
EP2185546A1 (en) 2010-05-19
CN101835774B (zh) 2014-09-17
EP2185546B1 (en) 2011-10-26
JP2010537987A (ja) 2010-12-09
WO2009032198A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
CL2008002549A1 (es) Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv.
ES2526759T3 (es) Composición para inducir la regeneración tisular por activación de plasma rico en plaquetas (PRP) y procedimiento para fabricarla
CN100453553C (zh) 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
CA2657213C (en) Peptide epoxyketones for proteasome inhibition
MX2010006489A (es) Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r) -4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopr opilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida.
SG11201810270SA (en) Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing
NO344397B1 (no) Forbindelser for Proteasom enzym-inhibering
PE20110217A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
CY1112999T1 (el) Αναστολεις ιου ηπατιτιδας c
CN105164117B (zh) 二肽和三肽环氧酮蛋白酶抑制剂
NO20090453L (no) Hepatitt C Virusinhibitorer
EA200900184A1 (ru) 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
EA201100153A1 (ru) Никотинсодержащие мягкие желатиновые пастилки
BRPI0410711A (pt) novos compostos
EP2542238A1 (en) Compounds for immunoproteasome inhibition
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
WO2007011878A8 (en) Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
BRPI0511466A (pt) agonistas peptìdicos do receptor de vasopressina
EP2697246B1 (en) Selective cysteine protease inhibitors and uses thereof
Bi et al. A new class of β-carboline alkaloid-peptide conjugates with therapeutic efficacy in acute limb ischemia/reperfusion injury
SG166105A1 (en) Antifungal composition
WO2006020207A3 (en) Compounds for control of appetite
PE20080250A1 (es) Proceso para la precipitacion y el aislamiento de compuestos 6,6-dimetil-3-azabiciclo [3.1.0] hexanamida mediante precipitacion controlada y formulaciones farmaceuticas que contienen dicho compuesto
Nishiuchi et al. Synthesis and antiviral activities of neoechinulin B and its derivatives